MIRM Quote, Financials, Valuation and Earnings

Krystal Biotech has a net margin of -23.93% compared to Mirum Pharmaceuticals's net margin of 49.9%. Mirum Pharmaceuticals's return on equity of -37.59% beat Krystal Biotech's return on equity of 10.49%.

Mirum Pharmaceuticals has a consensus price target of $63.78, signalling upside risk potential of 64.59%. On the other hand Krystal Biotech has an analysts' consensus of $215.20 which suggests that it could grow by 30.66%. Given that Mirum Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Mirum Pharmaceuticals is more attractive than Krystal Biotech.

Mirum Pharmaceuticals has a beta of 1.003, which suggesting that the stock is 0.33300000000001% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.751, suggesting its less volatile than the S&P 500 by 24.867%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $99.4M, which are larger than Krystal Biotech quarterly revenues of $91.1M. Mirum Pharmaceuticals's net income of -$23.8M is lower than Krystal Biotech's net income of $45.5M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 55.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.00x versus 16.84x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -23.93% compared to Mirum Pharmaceuticals's net margin of -49.65%. Mirum Pharmaceuticals's return on equity of -37.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Mirum Pharmaceuticals has a consensus price target of $63.78, signalling upside risk potential of 64.59%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Mirum Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Mirum Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 1.003, which suggesting that the stock is 0.33300000000001% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $99.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Mirum Pharmaceuticals's net income of -$23.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.00x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -23.93% compared to Mirum Pharmaceuticals's net margin of --. Mirum Pharmaceuticals's return on equity of -37.59% beat Palatin Technologies's return on equity of --.

Mirum Pharmaceuticals has a consensus price target of $63.78, signalling upside risk potential of 64.59%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Mirum Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 1.003, which suggesting that the stock is 0.33300000000001% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $99.4M, which are larger than Palatin Technologies quarterly revenues of --. Mirum Pharmaceuticals's net income of -$23.8M is higher than Palatin Technologies's net income of --. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.00x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -23.93% compared to Mirum Pharmaceuticals's net margin of -18.58%. Mirum Pharmaceuticals's return on equity of -37.59% beat Retractable Technologies's return on equity of -16.83%.

Mirum Pharmaceuticals has a consensus price target of $63.78, signalling upside risk potential of 64.59%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Mirum Pharmaceuticals has higher upside potential than Retractable Technologies, analysts believe Mirum Pharmaceuticals is more attractive than Retractable Technologies.

Mirum Pharmaceuticals has a beta of 1.003, which suggesting that the stock is 0.33300000000001% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $99.4M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Mirum Pharmaceuticals's net income of -$23.8M is lower than Retractable Technologies's net income of -$1.9M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.00x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.